Aktienanalyse zu Atara Biotherapeutics, Inc. (ATRA)ATRAAtara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Atara Biotherapeutics is currently not a strong buy due to mixed signals. The current price is $8.59, which is significantly below its 52-week high of $19.14, indicating a potential for recovery. However, the RSI is at 47.79, suggesting the stock is neither overbought nor oversold. The forward P/E ratio is 15.15, which is reasonable, but the company has a negative net income margin of -767.30% in Q2 2026, indicating ongoing financial struggles. The recent insider selling has increased by 29504.54%, which raises concerns about insider confidence. Therefore, while there are some positive catalysts, such as potential FDA approval, the risks outweigh the benefits at this time.

6 analysts cover ATRA: 4 rate it Buy, 1 Hold and 1 Sell. The average price target is 21.50.